These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38369644)

  • 1. Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.
    Niu L; Wu H; Gao R; Chen L; Wang J; Duan H; Long Y; Xie Y; Zhou Q; Zhou R
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):94. PubMed ID: 38369644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
    Zhao Y; Li S; Yang X; Chu L; Wang S; Tong T; Chu X; Yu F; Zeng Y; Guo T; Zhou Y; Zou L; Li Y; Ni J; Zhu Z
    Int J Cancer; 2022 Apr; 150(8):1318-1328. PubMed ID: 34914096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.
    Zhu Y; Liu C; Xu Z; Zou Z; Xie T; Xing P; Wang L; Li J
    Chin Med J (Engl); 2023 Nov; 136(21):2551-2561. PubMed ID: 37160733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
    Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Tozuka T; Noro R; Mizutani H; Kurimoto F; Hakozaki T; Hisakane K; Naito T; Takahashi S; Taniuchi N; Yajima C; Hosomi Y; Hirose T; Minegishi Y; Okano T; Kamio K; Yamaguchi T; Seike M;
    Lung Cancer; 2024 May; 191():107540. PubMed ID: 38614069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
    Song Y; Lin S; Chen J; Dang J
    BMC Cancer; 2023 Oct; 23(1):1043. PubMed ID: 37904083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors.
    Yun PJ; Wang GC; Chen YY; Wu TH; Huang HK; Lee SC; Chang H; Huang TW
    PLoS One; 2019; 14(5):e0215923. PubMed ID: 31048854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
    Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
    Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
    J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases.
    Yu F; Ni J; Zeng W; Zhou Y; Guo T; Zeng Y; Zhao Y; Li S; Li Y; Yang X; Zou L; Wang S; Liu Q; Li Y; Chu L; Chu X; Ye L; Yu W; Zhu Z
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):804-815. PubMed ID: 34058255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
    Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
    Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
    BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
    Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
    Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases.
    Zhang G; Cheng R; Zhang Z; Jiang T; Ren S; Ma Z; Zhao S; Zhou C; Zhang J
    Sci Rep; 2017 Feb; 7():42979. PubMed ID: 28211502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
    Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.